We scan new podcasts and send you the top 5 insights daily.
Frontline VEGF inhibition was historically avoided in squamous non-small cell lung cancer due to severe bleeding risks. In the HARMONY-6 study, excluding patients with large cavitary lesions or significant hemoptysis kept severe grade 3 or higher hemorrhage and arterial thromboembolism uncommon.
Despite subsequent data not confirming an increased bleeding risk compared to other therapies, the initial studies on pacritinib showed a signal for increased bleeding. Consequently, it is still advised that the drug be stopped for several days prior to any major surgical procedure as a safety precaution.
Subgroup analysis from LITESPARK 011 revealed a significantly stronger benefit (hazard ratio 0.47) for the Belzutifan combination in favorable-risk patients. This supports the hypothesis that these tumors are more purely dependent on the HIF/VEGF pathway, suggesting an angiogenic signature could emerge as a predictive biomarker for Belzutifan's efficacy.
The LEAP-010 trial excluded patients with vascular involvement due to the drug's bleeding risk. This is a common characteristic in real-world head and neck cancer patients, especially post-radiation. This discrepancy means that even if the drug combination had been successful, its applicability in routine clinical practice would be severely limited.
Historic VEGF inhibitors in lung cancer improved progression-free survival without yielding overall survival gains. The phase 3 HARMONY-6 trial broke this pattern by showing a statistically and clinically significant median overall survival improvement of 27 versus 23 months (hazard ratio 0.66) when combining ivonescimab with chemotherapy.
In the HARMONY A study, Ivanesimab plus chemotherapy significantly improved progression-free survival in EGFR-mutant non-small cell lung cancer patients. This is notable because prior trials showed that adding standard PD-1 inhibitors to chemotherapy was ineffective for this specific patient population.
Simultaneous targeting of VEGF and checkpoint inhibition raised concerns regarding compounded toxicities, but clinicians view the side-effect profile as familiar. Polling and trial results suggest ivonescimab's VEGF-related toxicities remain mostly low grade and are comparable to or more manageable than historical monoclonal antibodies like bevacizumab.
Bevacizumab is conventionally avoided in squamous non-small cell lung cancer due to fatal hemoptysis risks. Ivonescimab, a bispecific antibody targeting PD-1 and VEGF, relies on cooperative binding: VEGF enhances its PD-1 binding and PD-1 enhances VEGF binding. This concentrates VEGF and checkpoint blockade directly at the tumor microenvironment while sparing non-target tissues, producing statistically significant progression-free and overall survival gains in squamous disease without typical anti-VEGF vascular fatalities.
In third-line mCRC, drug selection is heavily guided by a patient's accumulated toxicities. For instance, a patient with bone marrow issues from prior chemotherapy might receive a VEGF inhibitor instead of another chemotherapy agent, prioritizing tolerability and quality of life.
Unlike bevacizumab's long 20-day half-life and associated bleeding risks that excluded squamous cell carcinoma patients, new bispecifics have a ~6-day half-life. This results in a similar but less severe toxicity profile, broadening their clinical application to a wider patient population.
Clinicians separate maintenance indications instead of combining agents by default. Bevacizumab is selected for higher-risk biology, such as residual disease or ascites where angiogenesis dominates, whereas low-risk HRD-deficient patients can rely solely on PARP inhibitors to prevent unnecessary toxicity.